Jazz Pharmaceuticals PLC (JAZZ) — SEC Filings

Overview

Jazz Pharmaceuticals PLC (JAZZ) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 17, 2025: On November 17, 2025, Jazz Pharmaceuticals plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant disclosures detailed in the provided text. The company is incorporated in Ireland and its principal executive off

Sentiment Summary

Across 46 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 42 neutral, 2 mixed. The dominant filing sentiment for Jazz Pharmaceuticals PLC is neutral.

Filing Type Overview

Jazz Pharmaceuticals PLC (JAZZ) has filed 1 144, 27 8-K, 6 10-Q, 1 DEFA14A, 2 DEF 14A, 2 10-K/A, 1 8-K/A, 2 10-K, 4 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (46)

• 144 Filing — 144 · Apr 1, 2026
• Jazz Pharmaceuticals Files 8-K — 8-K · Nov 17, 2025 Risk: low
  On November 17, 2025, Jazz Pharmaceuticals plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material e
• Jazz Pharma Swings to Loss on Soaring R&D Costs, Revenue Up — 10-Q · Nov 5, 2025 Risk: high
  Jazz Pharmaceuticals plc reported a mixed financial performance for the nine months ended September 30, 2025. Total revenues increased to $3,069,660,000 from $2
• Jazz Pharmaceuticals Announces Executive and Board Changes — 8-K · Oct 28, 2025 Risk: medium
  Jazz Pharmaceuticals plc announced on October 23, 2025, changes in its executive team and board of directors. The filing details the departure of certain office
• Jazz Pharmaceuticals Files 8-K Report — 8-K · Oct 22, 2025 Risk: low
  On October 21, 2025, Jazz Pharmaceuticals plc filed an 8-K report. The filing indicates that the company is located at Fifth Floor, Waterloo Exchange, Waterloo
• Jazz Pharma Q2 Revenue Dips Slightly to $950M Amidst Stable Product Sales — 10-Q · Aug 6, 2025 Risk: medium
  Jazz Pharmaceuticals plc reported total revenues of $950.0 million for the three months ended June 30, 2025, a decrease from $960.0 million in the prior-year pe
• Jazz Pharmaceuticals Files 8-K on Financials — 8-K · Aug 5, 2025 Risk: low
  On August 5, 2025, Jazz Pharmaceuticals plc filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
• Jazz Pharmaceuticals Schedules Shareholder Vote — 8-K · Jul 25, 2025 Risk: medium
  On July 24, 2025, Jazz Pharmaceuticals plc filed an 8-K report to announce a submission of matters to a vote of security holders. The filing was made public on
• Jazz Pharmaceuticals Files Definitive Proxy Materials — DEFA14A · Jul 14, 2025 Risk: low
  Jazz Pharmaceuticals plc filed a Definitive Additional Materials proxy statement on July 14, 2025. This filing is related to the company's proxy materials and d
• Jazz Pharma Announces Executive Changes — 8-K · Jul 10, 2025 Risk: medium
  Jazz Pharmaceuticals plc announced on July 8, 2025, changes in its executive team, including the appointment of a new Chief Medical Officer, Dr. Robert I. Smith
• Jazz Pharma Sets July 24 AGM, Focuses on Governance — DEF 14A · Jun 6, 2025 Risk: low
  Jazz Pharmaceuticals plc filed its DEF 14A on June 6, 2025, outlining the agenda for its Annual General Meeting on July 24, 2025, in Dublin, Ireland. The filing
• Jazz Pharma Q1 2025 Sales Dip — 10-Q · May 7, 2025 Risk: medium
  Jazz Pharmaceuticals plc filed its 10-Q for the period ending March 31, 2025. The company reported net product sales of $854.4 million for the first quarter of
• Jazz Pharmaceuticals Files 8-K on Financials — 8-K · May 6, 2025 Risk: low
  On May 6, 2025, Jazz Pharmaceuticals plc filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well
• Jazz Pharmaceuticals Files 2024 Annual Report Amendment — 10-K/A · Apr 25, 2025 Risk: low
  Jazz Pharmaceuticals plc filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, dated April 25, 2025, provide
• Jazz Pharmaceuticals Files 8-K Report — 8-K · Apr 21, 2025 Risk: low
  On April 21, 2025, Jazz Pharmaceuticals plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a
• Jazz Pharmaceuticals Enters Material Definitive Agreement — 8-K · Apr 8, 2025 Risk: medium
  On April 7, 2025, Jazz Pharmaceuticals plc entered into a material definitive agreement. The company, incorporated in Ireland with its principal executive offic
• Jazz Pharmaceuticals Files 8-K Amendment — 8-K/A · Mar 5, 2025 Risk: medium
  Jazz Pharmaceuticals plc filed an amendment (8-K/A) on March 5, 2025, to a previous filing concerning a material definitive agreement entered into on March 4, 2
• Jazz Pharmaceuticals plc Files 2024 10-K — 10-K · Feb 26, 2025 Risk: medium
  Jazz Pharmaceuticals plc filed its 2024 10-K on February 26, 2025, reporting on its fiscal year ending December 31, 2024. The company, incorporated in L2 and he
• Jazz Pharmaceuticals Files 8-K on Financials — 8-K · Feb 25, 2025 Risk: low
  Jazz Pharmaceuticals plc filed an 8-K on February 25, 2025, reporting on its results of operations and financial condition. The filing includes financial statem
• Jazz Pharmaceuticals Files 8-K — 8-K · Jan 13, 2025 Risk: low
  On January 13, 2025, Jazz Pharmaceuticals plc (JAZZ) filed a Form 8-K to report its status as a public company. The filing confirms the company's incorporation
• Jazz Pharmaceuticals Appoints New Chief Medical Officer and CLO — 8-K · Dec 16, 2024 Risk: low
  On December 11, 2024, Jazz Pharmaceuticals plc announced changes to its executive team. The company appointed two new officers: Dr. Robert I. Tepper as Chief Me
• Jazz Pharmaceuticals Enters Material Definitive Agreement — 8-K · Nov 26, 2024 Risk: medium
  On November 26, 2024, Jazz Pharmaceuticals plc entered into a material definitive agreement. This filing also indicates the creation of a direct financial oblig
• Jazz Pharmaceuticals Files 8-K Report — 8-K · Nov 21, 2024 Risk: low
  On November 20, 2024, Jazz Pharmaceuticals plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• Jazz Pharma Q3 Sales Rise to $930.5M — 10-Q · Nov 7, 2024 Risk: low
  Jazz Pharmaceuticals plc reported its third-quarter 2024 results, with product sales for the three months ended September 30, 2024, reaching $930.5 million, an
• Jazz Pharmaceuticals Files 8-K on Financials — 8-K · Nov 6, 2024 Risk: low
  Jazz Pharmaceuticals plc filed an 8-K on November 6, 2024, reporting on its results of operations and financial condition, as well as financial statements and e
• SC 13G/A Filing — SC 13G/A · Oct 21, 2024
• Jazz Pharmaceuticals Terminates Material Definitive Agreement — 8-K · Oct 16, 2024 Risk: medium
  Jazz Pharmaceuticals plc announced on October 10, 2024, the termination of a material definitive agreement. The filing does not specify the other party involved
• Jazz Pharmaceuticals Reports Key Financial and Corporate Events — 8-K · Sep 6, 2024 Risk: medium
  On September 3, 2024, Jazz Pharmaceuticals plc entered into a material definitive agreement related to its financing. The company also reported on the creation
• Jazz Pharma Closes $1B Senior Notes Offering, Secures New Credit Facility — 8-K · Aug 28, 2024 Risk: low
  On August 27, 2024, Jazz Pharmaceuticals plc announced the closing of its previously disclosed offering of $1.0 billion aggregate principal amount of 5.000% sen
• Jazz Pharma Q2 2024: Sales Hit $513M — 10-Q · Aug 1, 2024 Risk: medium
  Jazz Pharmaceuticals plc reported its financial results for the second quarter of 2024, ending June 30, 2024. The company's net product sales for the second qua
• Jazz Pharmaceuticals Files 8-K on Financials — 8-K · Jul 31, 2024 Risk: low
  Jazz Pharmaceuticals plc filed an 8-K on July 31, 2024, reporting on its results of operations and financial condition. The filing includes financial statements
• Jazz Pharmaceuticals Holds Shareholder Vote — 8-K · Jul 26, 2024 Risk: low
  On July 25, 2024, Jazz Pharmaceuticals plc filed an 8-K report indicating that matters were submitted to a vote of security holders. The filing does not disclos
• Jazz Pharmaceuticals Enters Material Definitive Agreement — 8-K · Jul 22, 2024 Risk: medium
  On July 19, 2024, Jazz Pharmaceuticals plc entered into a material definitive agreement related to a financial obligation. The company, incorporated in Ireland,
• DEF 14A Filing — DEF 14A · Jun 14, 2024
• Jazz Pharma Appoints New CLO, Renews CFO Agreement — 8-K · May 31, 2024 Risk: low
  Jazz Pharmaceuticals plc announced on May 31, 2024, changes in its executive team. The company appointed Renée Smith as Chief Legal Officer and General Counsel,
• Jazz Pharmaceuticals plc Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 2, 2024 Risk: low
  Jazz Pharmaceuticals plc (JAZZ) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Jazz Pharmaceuticals plc filed a 10-Q report for the quarter ended
• Jazz Pharmaceuticals Files 8-K on Financials — 8-K · May 1, 2024 Risk: low
  Jazz Pharmaceuticals plc filed an 8-K on May 1, 2024, reporting on its results of operations and financial condition. The filing includes financial statements a
• Jazz Pharmaceuticals plc Files Amendment to Annual Report — 10-K/A · Apr 26, 2024 Risk: low
  Jazz Pharmaceuticals plc (JAZZ) filed a Amended Annual Report (10-K/A) with the SEC on April 26, 2024. Jazz Pharmaceuticals plc filed an amendment (10-K/A) to i
• Jazz Pharmaceuticals plc Files 2023 Annual Report on Form 10-K — 10-K · Feb 28, 2024 Risk: medium
  Jazz Pharmaceuticals plc (JAZZ) filed a Annual Report (10-K) with the SEC on February 28, 2024. Jazz Pharmaceuticals plc filed its 2023 Form 10-K on February 28
• Jazz Pharma Files 8-K on Officer Changes and Compensation — 8-K · Feb 27, 2024 Risk: medium
  This 8-K filing by Jazz Pharmaceuticals plc, filed on February 27, 2024, reports events that occurred on February 23, 2024. The filing indicates changes related
• Jazz Pharma 8-K Hints at Executive Changes, Compensation Updates — 8-K · Feb 21, 2024 Risk: medium
  Jazz Pharmaceuticals plc filed an 8-K on February 21, 2024, reporting on Item 5.02, "Departure of Directors or Certain Officers; Election of Directors; Appointm
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Jazz Pharma Reports Material Agreement & New Financial Obligation — 8-K · Jan 25, 2024
  Jazz Pharmaceuticals plc filed an 8-K on January 25, 2024, reporting an event on January 19, 2024, related to entering a material definitive agreement and creat
• BlackRock Amends Jazz Pharma Stake, Signals Continued Confidence — SC 13G/A · Jan 24, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating its ownership of Jazz Pharmaceuticals plc's Common Stock as of December 31, 2023. This
• Jazz Pharma Files 8-K: Routine Update, Nasdaq Listing Confirmed — 8-K · Jan 8, 2024
  Jazz Pharmaceuticals plc filed an 8-K on January 8, 2024, to update its registration information, specifically confirming its status as a non-emerging growth co

Risk Profile

Risk Assessment: Of JAZZ's 38 recent filings, 1 were flagged as high-risk, 16 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Jazz Pharmaceuticals PLC's most recent 10-Q filing (Nov 5, 2025):

• Revenue: $3,069,660,000
• Net Income: $-559,599,000
• EPS: ($9.18)
• Debt-to-Equity: 1.09
• Cash Position: $1,326,070,000
• Operating Margin: -60.8%
• Total Assets: $11,356,485,000
• Total Debt: $5,361,161,000

Key Executives

• Dr. Robert I. Smith
• Dr. Karen M. Smith
• Dr. Robert I. Tepper
• Ms. Jennifer L. W. D. Smith
• Renée Smith
• Michael Miller

Industry Context

Jazz Pharmaceuticals operates in the highly competitive biopharmaceutical sector, focusing on specialty markets. The industry is characterized by significant R&D investment, lengthy drug development cycles, and stringent regulatory oversight. Companies like Jazz rely on innovation and strategic acquisitions to maintain and grow their product portfolios and market share.

Top Tags

financial-reporting (6) · sec-filing (5) · pharmaceuticals (5) · 8-k (5) · Pharmaceuticals (4) · 8-K (4) · corporate-governance (4) · material-agreement (4) · compensation (3) · SEC Filing (3)

Key Numbers

• Net Loss: $559.6M — Swung from $369M net income in 9M 2024 to a net loss in 9M 2025.
• Acquired IPR&D Expense: $947.9M — Massive increase from $10M in 9M 2024, driving the net loss.
• Total Revenues: $3.07B — Increased from $2.98B in 9M 2024, showing underlying sales growth.
• Cash and Cash Equivalents: $1.33B — Decreased from $2.41B at Dec 31, 2024, indicating cash utilization.
• Long-term Debt (less current portion): $4.33B — Reduced from $6.08B at Dec 31, 2024, improving the balance sheet.
• Selling, General & Administrative: $1.40B — Increased from $1.02B in 9M 2024, contributing to higher operating expenses.
• Share Repurchases (Q2 2025): $125.0M — Part of the New Repurchase Program, impacting shareholder equity.
• Basic EPS (Q3 2025): $4.14 — Positive for the quarter, despite the nine-month net loss.
• Basic EPS (9M 2025): ($9.18) — Reflects the significant net loss for the nine-month period.
• Ordinary Shares Outstanding: 60,765,116 — As of October 29, 2025, slightly lower than prior periods due to repurchases.
• Q2 2025 Total Revenue: $950.0M — Slight decrease from $960.0M in Q2 2024, indicating revenue pressure.
• Q2 2025 Product Sales: $940.0M — Maintained strong core sales, down slightly from $950.0M in Q2 2024.
• H1 2025 Total Revenue: $1,890.0M — Marginal decrease from $1,900.0M in H1 2024, showing a consistent trend.
• Accumulated Other Comprehensive Income (June 30, 2025): $5.0M — Decreased from $10.0M at Dec 31, 2024, suggesting potential market or currency impacts.
• Retained Earnings (June 30, 2025): $4,650.0M — Increased from $4,500.0M at Dec 31, 2024, reflecting ongoing profitability.

Related Companies

AVDL · CHRS · TAK · UCB

Frequently Asked Questions